The novel cryogenic pump enables IceCure to bring to market a new generation of cryoablation systems with a small footprint for a wide range of clinical applications. It also expands the Company’s portfolio of products to include a broader range of thinner cryoprobes and catheters.

IceCure’s novel cryogenic pump is submersible in liquid nitrogen (“LN2”), works in a closed circuit, enables temperature control of the cryoprobe, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill LN2.

“With over 50 granted patents for cryoablation systems and cryoprobes, we believe IceCure is the clear global leader in LN2-based cryoablation. Our intellectual property, a growing number of regulatory approvals and increasing commercial traction support our aim to improve healthcare by de-escalating surgery across indications through safe and effective cryoablation procedures,” stated Eyal Shamir, IceCure’s Chief Executive Officer.